期刊文献+
共找到14篇文章
< 1 >
每页显示 20 50 100
Objective Rating of the Launch Behavior of Conventional,Hybrid and Electric Vehicles 被引量:1
1
作者 Christian Dorsch Xiao Wang Ferit Kucukay 《Automotive Innovation》 CSCD 2021年第1期70-80,共11页
The calibration of conventional,hybrid and electric drivetrains is an important process during the development phase of any vehicle.Therefore,to optimize the comfort and dynamic behavior(known as driveability),many te... The calibration of conventional,hybrid and electric drivetrains is an important process during the development phase of any vehicle.Therefore,to optimize the comfort and dynamic behavior(known as driveability),many test drives are performed by experienced drivers during different driving maneuvers,e.g.,launch,re-launch or gear shift.However,the process can be kept more consistent and independent of human-based deviations by using objective ratings.This study first introduces an objective rating system developed for the launch behavior of conventional vehicles with automatic transmission,dual-clutch transmission,and alternative drivetrains.Then,the launch behavior,namely comfort and dynamic quality,is compared between two conventional vehicles,a plug-in hybrid electric vehicle and a battery electric vehicle.Results show the benefits of pure electric drivetrains due to the lack of launch and shifting elements,as well as the usage of a highly dynamic electric motor.While the plug-in hybrid achieves a 10%higher overall rating compared to the baseline conventional vehicle,the pure electric vehicle even achieves a 21%higher overall rating.The results also highlight the optimization potential of battery electric vehicles regarding their comfort and dynamic characteristics.The transitions and the gradient of the acceleration build-up have a major influence on the launch quality. 展开更多
关键词 objective rating Launch behavior Driveability Transmission calibration Drivetrain calibration
原文传递
Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers:An open-label,non-randomized,phase II clinical trial
2
作者 Ling-Xiao Xu Jia-Jia Yuan +1 位作者 Ran Xue Jun Zhou 《World Journal of Gastroenterology》 SCIE CAS 2024年第30期3564-3573,共10页
BACKGROUND Biliary tract cancers(BTCs)are a heterogeneous group of tumors with high malignancy,poor prognosis,and limited treatment options.AIM To explore the efficacy and safety of nab-paclitaxel plus capecitabine as... BACKGROUND Biliary tract cancers(BTCs)are a heterogeneous group of tumors with high malignancy,poor prognosis,and limited treatment options.AIM To explore the efficacy and safety of nab-paclitaxel plus capecitabine as first-line treatment for advanced and metastatic BTCs.METHODS This open-label,non-randomized,double-center,phase II clinical trial recruited systemic therapy-naive patients with unresectable or metastatic BTCs between April 2019 and June 2022 at Beijing Cancer Hospital and the First Hospital of China Medical University.Eligible patients were administered nab-paclitaxel(150 mg/m^(2),day 1)and capecitabine(2000 mg/m^(2),twice daily,days 1-7)in 14-day cycles until experiencing intolerable toxicity or disease progression.The primary outcome was the objective response rate(ORR).The secondary outcomes included the disease control rate(DCR),overall survival(OS),progression-free survival(PFS),and safety.RESULTS A total of 44 patients successfully completed the trial,with a median age of 64.00 years(interquartile range,35.00-76.00),and 26(59.09%)were females.Tumor response assessment was impeded for one patient due to premature demise from tumor hemorrhage.Among the remaining 43 patients undergoing at least one imaging assessment,the ORR was 23.26%[95%confidence interval(CI):11.80%-38.60%],and the DCR was 69.77%(95%CI:53.90%-82.80%).The median OS was 14.1 months(95%CI:8.3-19.9),and the median PFS was 4.4 months(95%CI:2.5-6.3).A total of 41 patients(93.18%)experienced at least one adverse event(AE),with 10 patients(22.73%)encountering grade≥3 AEs,and the most frequent AEs of any grade were alopecia(79.50%),leukopenia(54.55%),neutropenia(52.27%),and liver dysfunction(40.91%),and no treatment-related deaths were documented.CONCLUSION Nab-paclitaxel plus capecitabine may be an effective and safe first-line treatment strategy for patients with advanced or metastatic BTCs. 展开更多
关键词 NAB-PACLITAXEL CAPECITABINE Biliary tract cancer objective response rate Phase II clinical trial
下载PDF
Effectiveness and tolerability of programmed cell death protein-1 inhibitor+chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers
3
作者 Xiao-Min Zhang Ting Yang +5 位作者 Ying-Ying Xu Bao-Zhong Li Wei Shen Wen-Qing Hu Cai-Wen Yan Liang Zong 《World Journal of Gastrointestinal Oncology》 SCIE 2024年第4期1613-1625,共13页
BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,i... BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,it is unclear whether this combination is superior to chemotherapy alone.AIM To assess the comparative effectiveness and tolerability of combining PD-1 inhibitors with chemotherapy vs chemotherapy alone in patients with advanced gastric cancer,gastroesophageal junction(GEJ)cancer,or oesophageal carcinoma.METHODS We searched the PubMed and Embase databases for studies that compared the efficacy and tolerance of PD-1 inhibitors in combination with chemotherapy vs chemotherapy alone in patients with advanced oesophageal or gastric cancer.We employed either random or fixed models to analyze the outcomes of each clinical trial,en-compassing data on overall survival(OS),progression-free survival(PFS),objective response rate,and adverse events(AEs).RESULTS Nine phase 3 clinical trials(7016 advanced oesophageal and gastric cancer patients)met the inclusion criteria.Our meta-analysis demonstrated that the pooled PD-1 inhibitor+chemotherapy group had a significantly longer OS than the chemotherapy-alone group[hazard ratio(HR)=0.76,95%confidence interval(CI):0.71-0.81];the pooled PFS result was consistent with that of OS(HR=0.67,95%CI:0.61-0.74).The count of patients achieving an objective response in the PD-1 inhibitor+chemotherapy group surpassed that of the chemotherapy-alone group[odds ratio(OR)=1.86,95%CI:1.59-2.18].AE incidence was also higher in the combination-therapy group than in the chemotherapy-alone group,regardless of whether≥grade 3 only(OR=1.30,95%CI:1.07-1.57)or all AE grades(OR=1.88,95%CI:1.39-2.54)were examined.We performed a subgroup analysis based on the programmed death-ligand 1(PD-L1)combined positive score(CPS)and noted extended OS and PFS durations within the CPS≥1,CPS≥5,and CPS≥10 subgroups of the PD-1 inhibitor+chemotherapy group.CONCLUSION In contrast to chemotherapy alone,the combination of PD-1 inhibitor and chemotherapy appears to present a more favorable option for initial or subsequent treatment in patients with gastric cancer,GEJ tumor,or oesophageal cancer.This holds true particularly for individuals with PD-L1 CPS scores of≥5 and≥10. 展开更多
关键词 Programmed cell death protein-1 inhibitor CHEMOTHERAPY Oesophageal squamous cell carcinoma Gastric/gastroesophageal junction adenocarcinoma Overall survival Progression-free survival objective response rate Adverse event
下载PDF
Evaluation of oxaliplatin and tigio combination therapy in locally advanced gastric cancer
4
作者 Teng Wang Li-Yun Zhang 《World Journal of Gastrointestinal Surgery》 SCIE 2024年第6期1709-1716,共8页
BACKGROUND Locally advanced gastric cancer(LAGC)is a common malignant tumor.In recent years,neoadjuvant chemotherapy has gradually become popular for the treatment of LAGC.AIM To investigate the efficacy of oxaliplati... BACKGROUND Locally advanced gastric cancer(LAGC)is a common malignant tumor.In recent years,neoadjuvant chemotherapy has gradually become popular for the treatment of LAGC.AIM To investigate the efficacy of oxaliplatin combined with a tigio neoadjuvant chemotherapy regimen vs a conventional chemotherapy regimen for LAGC.METHODS Ninety patients with LAGC were selected and randomly divided into control and study groups with 45 patients in each group,according to the numerical table method.The control group was treated with conventional chemotherapy,and the study group was treated with oxaliplatin combined with tigio-neoadjuvant che-motherapy.The primary outcome measures were the clinical objective response rate(ORR)and surgical resection rate(SRR),whereas the secondary outcome measures were safety and Karnofsky Performance Status score.RESULTS The ORR in the study group was 80.00%,which was significantly higher than that of the control group(57.78%).In the study group,SRR was 75.56%,which was significantly higher than that of the control group(57.78%).There were 15.56%adverse reactions in the study group and 35.56%in the control group.These differences were statistically significant between the two groups.CONCLUSION The combination of oxaliplatin and tigio before surgery as neoadjuvant chemotherapy for patients with LAGC can effectively improve the ORR and SRR and is safe. 展开更多
关键词 Locally advanced gastric cancer Oxaliplatin and tigio Neoadjuvant chemotherapy Surgical resection rate objective response rate Clinical efficacy
下载PDF
Objective response rate assessment in oncology: Current situation and future expectations 被引量:2
5
作者 Nuri Faruk Aykan Tahsin ?zatl? 《World Journal of Clinical Oncology》 2020年第2期53-73,共21页
The tumor objective response rate(ORR)is an important parameter to demonstrate the efficacy of a treatment in oncology.The ORR is valuable for clinical decision making in routine practice and a significant end-point f... The tumor objective response rate(ORR)is an important parameter to demonstrate the efficacy of a treatment in oncology.The ORR is valuable for clinical decision making in routine practice and a significant end-point for reporting the results of clinical trials.World Health Organization and Response Evaluation Criteria in Solid Tumors(RECIST)are anatomic response criteria developed mainly for cytotoxic chemotherapy.These criteria are based on the visual assessment of tumor size in morphological images provided by computed tomography(CT)or magnetic resonance imaging.Anatomic response criteria may not be optimal for biologic agents,some disease sites,and some regional therapies.Consequently,modifications of RECIST,Choi criteria and Morphologic response criteria were developed based on the concept of the evaluation of viable tumors.Despite its limitations,RECIST v1.1 is validated in prospective studies,is widely accepted by regulatory agencies and has recently shown good performance for targeted cancer agents.Finally,some alternatives of RECIST were developed as immune-specific response criteria for checkpoint inhibitors.Immune RECIST criteria are based essentially on defining true progressive disease after a confirmatory imaging.Some graphical methods may be useful to show longitudinal change in the tumor burden over time.Tumor tissue is a tridimensional heterogenous mass,and tumor shrinkage is not always symmetrical;thus,metabolic response assessments using positron emission tomography(PET)or PET/CT may reflect the viability of cancer cells or functional changes evolving after anticancer treatments.The metabolic response can show the benefit of a treatment earlier than anatomic shrinkage,possibly preventing delays in drug approval.Computer-assisted automated volumetric assessments,quantitative multimodality imaging in radiology,new tracers in nuclear medicine and finally artificial intelligence have great potential in future evaluations. 展开更多
关键词 objective response rate Tumor shrinkage World Health Organization criteria Response Evaluation Criteria in Solid Tumors Immune Response Evaluation Criteria in Solid Tumors criteria Early tumor shrinkage Depth of response Waterfall plot Spider plot Swimmer plot
下载PDF
Common toxicities and objective response rate in metastatic colorectal cancer patients treated with irinotecan based regimens
6
作者 Liu Huang Xin Liao +5 位作者 Qianqian Yu Qiang Fu Kai Qin Huanlei Wu Lihong Zhang Xianglin Yuan 《The Chinese-German Journal of Clinical Oncology》 CAS 2013年第3期109-112,共4页
Objective: The aim of our study was to investigate if common toxicities are correlated to objective response rate (ORR) in metastatic colorectal cancer (mCRC) patients treated by irinotecan based regimens. Method... Objective: The aim of our study was to investigate if common toxicities are correlated to objective response rate (ORR) in metastatic colorectal cancer (mCRC) patients treated by irinotecan based regimens. Methods: Univadate and multivariate logistic regression analyses were performed to evaluate correlations between common toxicities and binary ORR in 106 mCRC patients from a prospective cohort treated with irinotecan based regimens. Results: The most frequent severe toxicities (Grade 3/4) were as follows: neutropenia (27.4%), diarrhea (16.9%), leucopenia (12.6%), vomiting (3.2%) and thrombocytopenia (2.1%). Thrombocytosis was observed in 25 (26.3%) patients. ORR was 25.3%. Thrombocytopenia (P = 0.014), line of chemotherapy (P = 0.028) and thrembocytosis (P = 0.033) were correlated with ORR in univariate analysis. In multivariate analysis, thrombocytopenia (odds ratio [OR] = 8.600, 95% confidence interval [CI] = 1.705-43.385, P = 0.009) and first line chemotherapy (OR = 5.155, 95% CI = 1.153-23.256, P = 0.032) positively related to ORR. Conclusion: Threm- bocytopenia may be an indicator of ORR in mCRC patients treated by irinotecan plus 5-fluorouracil/capecitabine. Evidence is not strong enough to prove that irinotecan based regimens-induced diarrhea, leucopenia, neutropenia or vomiting is associ- ated with ORR. 展开更多
关键词 colorectal cancer (CRC) IRINOTECAN objective response rate (ORR) toxicity THROMBOCYTOPENIA
下载PDF
ON THE OBJECTIVE STRESS RATE IN CO-MOVING COORDINATE SYSTEM
7
作者 尚勇 陈至达 《Applied Mathematics and Mechanics(English Edition)》 SCIE EI 1989年第2期103-112,共10页
The objective stress rate is a rather important problem in mechanics of finite deformation. In this paper, the objective stress rate in co-moving coordinate is derived by applying nonlinear geometric field theory of d... The objective stress rate is a rather important problem in mechanics of finite deformation. In this paper, the objective stress rate in co-moving coordinate is derived by applying nonlinear geometric field theory of deformation. Problems, such ax targe extension coupled with rotation, and large shear deformation, are exemplified by using the new formula. Comparing with Jaumann 's stress rate and other formulae presented in current literature, the new result appears to be the reasonable one in co-moving coordinate system. 展开更多
关键词 ON THE objective STRESS RATE IN CO-MOVING COORDINATE SYSTEM RATE
下载PDF
Ensuring the Macro-economic Objectives of 8-percent GDP Growth and 3-percent Inflation Rate
8
《开放导报》 1998年第4期1-1,共1页
关键词 GDP Ensuring the Macro-economic objectives of 8-percent GDP Growth and 3-percent Inflation Rate
下载PDF
ANALYSIS OF SIMPLE SHEAR ENDOCHRONIC EQUATIONSFOR FINITE PLASTIC DEFORMATION
9
作者 江五贵 黄明挥 《Applied Mathematics and Mechanics(English Edition)》 SCIE EI 2005年第1期85-91,共7页
Jaumann rate, generalized Jaumann rate,Fu rate and Wu rate were incorporated into endochronic equations for finite plastic deformation to analyze simple shear finite deformation. The results show that an oscillatory s... Jaumann rate, generalized Jaumann rate,Fu rate and Wu rate were incorporated into endochronic equations for finite plastic deformation to analyze simple shear finite deformation. The results show that an oscillatory shear stress and normal stress response to a monotonically increasing shear strain occurs when Jaumann rate objective model is adopted for hypoelastic or endochronic materials. The oscillatory response is dependent on objective rate adopted,independent on elastoplastic models. Normal stress is unequal to zero during simple shear finite deformation. 展开更多
关键词 finite deformation endochronic equation simple shear oscillation objective rate
下载PDF
Simple shear endochronic equations for finite plastic deformation
10
作者 JIANGWugui FUMingfu +1 位作者 CHENLiangsen GENGShiqi 《Journal of Chongqing University》 CAS 2004年第1期78-81,共4页
The endochronic equations proposed by Valanis (1980) were extended to a finite deformation range. Jaumanns rate, Fus rate and Wus rate were incorporated into the endochronic equations to analyze simple shear finite de... The endochronic equations proposed by Valanis (1980) were extended to a finite deformation range. Jaumanns rate, Fus rate and Wus rate were incorporated into the endochronic equations to analyze simple shear finite deformation. Incremental equations and numerical solutions are deduced for three endochronic objective models. The results show that an oscillatory shear stress response to a monotonically increasing shear strain occurs when the Jaumanns rate objective model is employed for endochronic materials. The oscillatory response is dependent on the adopted objective rate. Compared with the Jaumanns rate, the Fus rate and the Wus rate satisfy the restrictions to elastic-plastic constitutive relations and are in agreement with the experimental results. 展开更多
关键词 finite deformation endochronic equations simple shear oscillation objective rates
下载PDF
Adaptive learning rate GMM for moving object detection in outdoor surveillance for sudden illumination changes 被引量:1
11
作者 HOCINE Labidi 曹伟 +2 位作者 丁庸 张笈 罗森林 《Journal of Beijing Institute of Technology》 EI CAS 2016年第1期145-151,共7页
A dynamic learning rate Gaussian mixture model(GMM)algorithm is proposed to deal with the problem of slow adaption of GMM in the case of moving object detection in the outdoor surveillance,especially in the presence... A dynamic learning rate Gaussian mixture model(GMM)algorithm is proposed to deal with the problem of slow adaption of GMM in the case of moving object detection in the outdoor surveillance,especially in the presence of sudden illumination changes.The GMM is mostly used for detecting objects in complex scenes for intelligent monitoring systems.To solve this problem,a mixture Gaussian model has been built for each pixel in the video frame,and according to the scene change from the frame difference,the learning rate of GMM can be dynamically adjusted.The experiments show that the proposed method gives good results with an adaptive GMM learning rate when we compare it with GMM method with a fixed learning rate.The method was tested on a certain dataset,and tests in the case of sudden natural light changes show that our method has a better accuracy and lower false alarm rate. 展开更多
关键词 object detection background modeling Gaussian mixture model(GMM) learning rate frame difference
下载PDF
Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer 被引量:1
12
作者 Zhe Huang Fang Wu +7 位作者 Qinqin Xu Lianxi Song Xiangyu Zhang Zhan Wang Li Deng Yongchang Zhang Liang Zeng Nong Yang 《Chinese Medical Journal》 SCIE CAS CSCD 2023年第12期1422-1429,共8页
Background:Immune checkpoint inhibitors(ICIs)are increasingly used as first-line therapy for patients with advanced non-small cell lung cancer(NSCLC)harboring no actionable mutations;however,data on their efficacy amo... Background:Immune checkpoint inhibitors(ICIs)are increasingly used as first-line therapy for patients with advanced non-small cell lung cancer(NSCLC)harboring no actionable mutations;however,data on their efficacy among patients presenting with intracranial lesions are limited.This study aimed to explore the efficacy and safety of ICIs combined with chemotherapy in advanced NSCLC patients with measurable brain metastasis at initial diagnosis.Methods:Our study retrospectively analyzed clinical data of a total of 211 patients diagnosed with driver gene mutation-negative advanced NSCLC with measurable,asymptomatic brain metastasis at baseline from Hunan Cancer Hospital between January 1,2019 and September 30,2021.The patients were stratified into two groups according to the first-line treatment regimen received:ICI combined with chemotherapy(n=102)or chemotherapy(n=109).Systemic and intracranial objective response rates(ORRs)and progression-free survival(PFS)were analyzed.Adverse events were also compared between the groups.Results:Compared with the chemotherapy-based regimen,the ICI-containing regimen was associated with a significantly higher intracranial(44.1%[45/102]vs.28.4%[31/109],χ^(2)=5.620,P=0.013)and systemic(49.0%[50/102]vs.33.9%[37/109],χ^(2)=4.942,P=0.019)ORRs and longer intracranial(11.0 months vs.7.0 months,P<0.001)and systemic(9.0 months vs.5.0 months,P<0.001)PFS.Multivariable analysis consistently revealed an independent association between receiving ICI plus platinum-based chemotherapy as a first-line regimen and prolonged intracranial PFS(hazard ratio[HR]=0.52,95%confidence interval[CI]:0.37-0.73,P<0.001)and systemic PFS(HR=0.48,95%CI:0.35-0.66,P<0.001).No unexpected serious adverse effects were observed.Conclusion:Our study provides real-world clinical evidence that ICI combined with chemotherapy is a promising first-line treatment option for driver gene mutation-negative advanced NSCLC patients who present with brain metastasis at initial diagnosis.Clinical trial registration:https://www.clinicaltrials.gov/,OMESIA,NCT05129202. 展开更多
关键词 Brain metastasis Immune checkpoint inhibitor Non-small cell lung cancer objective response rates Progression-free survival
原文传递
Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma 被引量:48
13
作者 Bo Zhang Ling Qi +6 位作者 Xi Wang Jianping Xu Yun Liu Lan Mu Xingyuan Wang Lidan Bai Jing Huang 《Cancer Communications》 SCIE 2020年第12期711-720,共10页
Background:Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma(ESCC).The incorporation of an immune checkpoint inhibitor and a molecular anti-angiogenic agent into t... Background:Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma(ESCC).The incorporation of an immune checkpoint inhibitor and a molecular anti-angiogenic agent into the commonly adopted chemotherapy may produce synergistic effects.Therefore,we aimed to investigate the efficacy and safety of camrelizumab plus apatinib combined with chemotherapy as the first-line treatment of advanced ESCC.Methods:In this single-arm prospective phase II trial,patients with unresectable locally advanced or recurrent/metastatic ESCC received camrelizumab 200 mg,liposomal paclitaxel 150 mg/m2,and nedaplatin 50 mg/m2 on day 1,and apatinib 250 mg on days 1-14.The treatments were repeated every 14 days for up to 9 cycles,followed by maintenance therapy with camrelizumab and apatinib.The primary endpoint was objective response rate(ORR)according to the Response Evaluation Criteria in Solid Tumors(version 1.1).Secondary endpoints included disease control rate(DCR),progression-free survival(PFS),overall survival(OS),and safety.Results:We enrolled 30 patients between August 7,2018 and February 23,2019.The median follow-up was 24.98 months(95%confidence interval[CI]:23.05-26.16 months).The centrally assessed ORR was 80.0%(95%CI:61.4%-92.3%),with a median duration of response of 9.77 months(range:1.54 to 24.82+months).The DCR reached 96.7%(95%CI:82.8%-99.9%).The median PFS was 6.85 months(95%CI:4.46-14.20 months),and the median OS was 19.43 months(95%CI:9.93 months–not reached).The most common grade 3-4 treatmentrelated adverse events(AEs)were leukopenia(83.3%),neutropenia(60.0%),and increased aspartate aminotransferase level(26.7%).Treatment-related serious AEs included febrile neutropenia,leukopenia,and anorexia in one patient(3.3%),and single cases of increased blood bilirubin level(3.3%)and toxic epidermal necrolysis(3.3%).No treatment-related deaths occurred.Conclusions:Camrelizumab plus apatinib combined with liposomal paclitaxel and nedaplatin as first-line treatment demonstrated feasible anti-tumor activity and manageable safety in patients with advanced ESCC.Randomized trials to evaluate this new combination strategy are warranted.Trial registration:This trial was registered on July 27,2018,at ClinicalTrials.gov(identifier:NCT03603756). 展开更多
关键词 ANTI-ANGIOGENESIS apatinib camrelizumab CHEMOTHERAPY esophageal squamous cell carcinoma FIRST-LINE immunotherapy liposomal paclitaxel NEDAPLATIN objective response rate
原文传递
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer(ESWN 01):a prospective randomized,multicenter,open-labeled phase 3 trial 被引量:11
14
作者 Jing Huang Binghe Xu +15 位作者 Ying Liu Junxing Huang Ping Lu Yi Ba Lin Wu Yuxian Bai Shu Zhang Jifeng Feng Ying Cheng Jie Li Lu Wen Xianglin Yuan Changwu Ma Chunhong Hu Qingxia Fan Xi Wang 《Cancer Communications》 SCIE 2019年第1期151-160,共10页
Background:The benefit of systemic treatments in esophageal squamous cell carcinoma(ESCC)which has pro-gressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been es... Background:The benefit of systemic treatments in esophageal squamous cell carcinoma(ESCC)which has pro-gressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established.We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monotherapy in recurrent or metastatic ESCC patients who had resistance to platinum-or taxane-based chemotherapy.Methods:We conducted a prospective randomized,multicenter,open-label,phase 3 trial in 15 centers across China.Eligible patients were adults with histologically confirmed recurrent or metastatic ESCC,and were randomly assigned(ratio,1:1)to receive either irinotecan plus S-1(intravenous infusion of irinotecan[160 mg/m2]on day 1 and oral S-1[80-120 mg]on days 1-10,repeated every 14 days)or oral S-1 monotherapy(80-120 mg/day on days 1-14,repeated every 21 days)using a central computerized minimization procedure.The primary endpoint was progression-free survival(PFS).Results:Between December 23,2014 and July 25,2016,we screened 148 patients and randomly assigned 123 patients to receive either irinotecan plus S-1 regimen(n=61)or S-1 monotherapy(n=62).After a median follow-up of 29.2 months(95%confidence interval[CI]17.5-40.9 months),the median PFS was significantly longer in the irinotecan plus S-1 group than in the S-1 monotherapy group(3.8 months[95%CI 2.9-4.3 months]vs.1.7 months[95%CI 1.4-2.7 months],hazard ratio=0.58,95%CI 0.38-0.86,P=0.006).The objective response rates were 24.6%in the irinotecan plus S-1 group and 9.7%in the S-1 monotherapy group(P=0.002).The patients in the irinotecan plus S-1 group presented with increased rates of grade 3-4 leukopenia(16.4%vs.0%),neutropenia(14.8%vs.1.6%),and nausea(4.9%vs.0%).No significant difference in grade 3-4 diarrhea and no treatment-related deaths were observed in both groups.Conclusions: The combination of irinotecan with S-1 was similarly tolerable but significantly prolonged PFS compared to S-1 monotherapy as a second- or third-line treatment in patients with recurrent or metastatic ESCC. 展开更多
关键词 Esophageal squamous cell carcinoma RECURRENT Metastasis MULTICENTER OPEN-LABEL randomized trial IRINOTECAN S-1 Overall survival Progression-free survival objective response rate Disease control rate
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部